Fig. 2

Application of MCC950 decreased Ang II-induced hypertensive retinopathy, ROS production and inflammation. A The mice were treated with NLRP3 inhibitor MCC950 (10 mg/kg/day, intraperitoneal injections) one day before Ang II infusion, and then once/day for 3 weeks. B SBP of each group was recorded (n = 6). C Images of hematoxylin and eosin (H&E) staining of central retinal sections (left), the thickness was quantified (n = 6). D Dihydroethidium (DHE) staining of retina in each group (left), the quantification of DHE intensity (n = 6). E Typical retinal angiograms and fundus photos (left), these white arrows indicate vascular fluorescein leakage and the corresponding area in the fundus photo. The ratio of retinal arteriovenous and fluorescence intensity was quantified (right; n = 6). F qPCR analyses of inflammatory mRNA of Il6 and Tnf (n = 6). G qPCR analyses of oxidative stress mRNA of Nox1 and Nox4 (n = 6). ***P < 0.0001 vs control; ^nsP > 0.05, ^#P < 0.05, ^##P < 0.01, ^###P < 0.0001 vs Ang II group